Ethacridine inhibits SARS-CoV-2 by inactivating viral particles.
The respiratory disease COVID-19 is caused by the coronavirus SARS-CoV-2. Here we report the discovery of ethacridine as a potent drug against SARS-CoV-2 (EC50 ~ 0.08 μM). Ethacridine was identified via high-throughput screening of an FDA-approved drug library in living cells using a fluorescence as...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-09-01
|
| Series: | PLoS Pathogens |
| Online Access: | https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1009898&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849330070376677376 |
|---|---|
| author | Xiaoquan Li Peter V Lidsky Yinghong Xiao Chien-Ting Wu Miguel Garcia-Knight Junjiao Yang Tsuguhisa Nakayama Jayakar V Nayak Peter K Jackson Raul Andino Xiaokun Shu |
| author_facet | Xiaoquan Li Peter V Lidsky Yinghong Xiao Chien-Ting Wu Miguel Garcia-Knight Junjiao Yang Tsuguhisa Nakayama Jayakar V Nayak Peter K Jackson Raul Andino Xiaokun Shu |
| author_sort | Xiaoquan Li |
| collection | DOAJ |
| description | The respiratory disease COVID-19 is caused by the coronavirus SARS-CoV-2. Here we report the discovery of ethacridine as a potent drug against SARS-CoV-2 (EC50 ~ 0.08 μM). Ethacridine was identified via high-throughput screening of an FDA-approved drug library in living cells using a fluorescence assay. Plaque assays, RT-PCR and immunofluorescence imaging at various stages of viral infection demonstrate that the main mode of action of ethacridine is through inactivation of viral particles, preventing their binding to the host cells. Consistently, ethacridine is effective in various cell types, including primary human nasal epithelial cells that are cultured in an air-liquid interface. Taken together, our work identifies a promising, potent, and new use of the old drug via a distinct mode of action for inhibiting SARS-CoV-2. |
| format | Article |
| id | doaj-art-552d796afa0a42e6b7dcd1f4fccebbef |
| institution | Kabale University |
| issn | 1553-7366 1553-7374 |
| language | English |
| publishDate | 2021-09-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Pathogens |
| spelling | doaj-art-552d796afa0a42e6b7dcd1f4fccebbef2025-08-20T03:47:04ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742021-09-01179e100989810.1371/journal.ppat.1009898Ethacridine inhibits SARS-CoV-2 by inactivating viral particles.Xiaoquan LiPeter V LidskyYinghong XiaoChien-Ting WuMiguel Garcia-KnightJunjiao YangTsuguhisa NakayamaJayakar V NayakPeter K JacksonRaul AndinoXiaokun ShuThe respiratory disease COVID-19 is caused by the coronavirus SARS-CoV-2. Here we report the discovery of ethacridine as a potent drug against SARS-CoV-2 (EC50 ~ 0.08 μM). Ethacridine was identified via high-throughput screening of an FDA-approved drug library in living cells using a fluorescence assay. Plaque assays, RT-PCR and immunofluorescence imaging at various stages of viral infection demonstrate that the main mode of action of ethacridine is through inactivation of viral particles, preventing their binding to the host cells. Consistently, ethacridine is effective in various cell types, including primary human nasal epithelial cells that are cultured in an air-liquid interface. Taken together, our work identifies a promising, potent, and new use of the old drug via a distinct mode of action for inhibiting SARS-CoV-2.https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1009898&type=printable |
| spellingShingle | Xiaoquan Li Peter V Lidsky Yinghong Xiao Chien-Ting Wu Miguel Garcia-Knight Junjiao Yang Tsuguhisa Nakayama Jayakar V Nayak Peter K Jackson Raul Andino Xiaokun Shu Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. PLoS Pathogens |
| title | Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. |
| title_full | Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. |
| title_fullStr | Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. |
| title_full_unstemmed | Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. |
| title_short | Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. |
| title_sort | ethacridine inhibits sars cov 2 by inactivating viral particles |
| url | https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1009898&type=printable |
| work_keys_str_mv | AT xiaoquanli ethacridineinhibitssarscov2byinactivatingviralparticles AT petervlidsky ethacridineinhibitssarscov2byinactivatingviralparticles AT yinghongxiao ethacridineinhibitssarscov2byinactivatingviralparticles AT chientingwu ethacridineinhibitssarscov2byinactivatingviralparticles AT miguelgarciaknight ethacridineinhibitssarscov2byinactivatingviralparticles AT junjiaoyang ethacridineinhibitssarscov2byinactivatingviralparticles AT tsuguhisanakayama ethacridineinhibitssarscov2byinactivatingviralparticles AT jayakarvnayak ethacridineinhibitssarscov2byinactivatingviralparticles AT peterkjackson ethacridineinhibitssarscov2byinactivatingviralparticles AT raulandino ethacridineinhibitssarscov2byinactivatingviralparticles AT xiaokunshu ethacridineinhibitssarscov2byinactivatingviralparticles |